贝伐珠单抗在晚期非小细胞肺癌中的疗效、安全性及对转移相关血液指标表达的影响研究  

Study on the Effect and Safety of Bevacizumab in the Treatment of Patients with Advanced NonSmall-Cell Lung Cancer and Influence for the Expression of Metastasis Related Blood Indexes

作　　者：傅雅雯 FU Yawen(Department of Respiratory and Critical Care Medicine,Quanzhou First Hospital,Quanzhou,Fujian 362000,China)

机构地区：[1]福建省泉州市第一医院呼吸与危重症医学科,福建泉州362000

出　　处：《中国医药指南》2025年第9期66-68,共3页Guide of China Medicine

摘　　要：目的探究贝伐珠单抗在晚期非小细胞肺癌中的疗效、安全性及对转移相关血液指标表达的影响。方法选取2022年3月至2023年12月的82例于泉州市第一医院治疗的晚期非小细胞肺癌患者作为研究对象,按照随机数字表法分组。对照组(41例)行常规非小细胞肺癌化疗,观察组(41例)则在对照组的基础上应用贝伐珠单抗。比较两组的非小细胞肺癌治疗效果、不良反应发生率、治疗前后的转移相关血液指标及功能生活状态。结果观察组的客观有效率及疾病控制率高于对照组(P<0.05),两组的六类不良反应发生率分别比较差异无统计学意义(P>0.05),治疗后观察组的VEGF、CD44v6、CCL20、MMP-2及MMP-9分别低于对照组,FACT-L量表评分高于对照组(P<0.05)。结论贝伐珠单抗在晚期非小细胞肺癌中的疗效较好,安全性较高,可有效控制转移相关血液指标的表达及改善功能生活状态。Objective To investigate the effect and safety of bevacizumab in the treatment of patients with advanced non-small-cell lung cancer and influence for the expression of metastasis related blood indexes.Methods Eighty-two patients with advanced non-small-cell lung cancer in Department of Respiratory and Critical Care Medicine,Quanzhou First Hospital from March 2022 to December 2023 were chosen as the study object,and all the patients were divided into groups by the random number table.The control group(41 cases)were treated with routine chemotherapy for non-small-cell lung cancer,the observation group(41 cases)were treated with bevacizumab on the treatment of control group.Then the treatment effect,adverse reaction incidence rate,metastasis related blood indexes function and life state before and after the treatment of two groups were compared.Results The objective effective rate and disease control rate of observation group were both higher than of control group(P<0.05),there were respectively no significant difference in the six kinds of adverse reactions between the two groups(P>0.05),after treatment,VEGF,CD44v6,CCL20,MMP-2 and MMP-9 in the observation group were lower than those in the control group,and FACT-L dose scale scores were higher than those in the control group(P<0.05).Conclusions The effect of bevacizumab in the treatment of patients with advanced non-small-cell lung cancer is better,its safety is higher,and it can effectively control the expression of metastasis related blood indexes and improve the function and life state of patients.

关 键 词：贝伐珠单抗 晚期非小细胞肺癌 疗效 安全性 转移相关血液指标 

分 类 号：R734.2[医药卫生—肿瘤]